Introduction:
Quality of treatment in patients with OC is one of the main prognostic factors. The
Qualitätssicherung Ovar (QS Ovar) was implemented as a nationwide initiative in 2000
in Germany and repeated about every 4 years.
Methods:
All hospitals in Germany were asked to document their patients anonymously with first
diagnosis of OC in Q3/2016.
Results:
267 hospitals documented 940 pts (> 60% of all pts in Germany). Surgical staging according
to guidelines was done in 69.6% of patients with early OC (FIGO I-IIA). There was
a significant improvement (p < 0.001) compared to earlier years (e.g. 38.8% in 2004).
Missing procedures were e.g. peritoneal biopsies (27.1%) and para-aortic lymphadenectomy
(25.2%). 78.5% received the standard chemotherapy. 4-year overall survival (OS) in
patients with standard therapy was 92.0% vs. 78.5% in patients not treated according
to guidelines (p = 0.003). 77.2% were diagnosed at advanced FIGO stage IIB-IV. The
rate of complete resection was 44.5%, which has also improved compared to earlier
years (p = 0.004). 90.8% of the patients treated with chemotherapy received the recommended
standard of at least carboplatin and paclitaxel and 64.6% received in addition bevacizumab.
Conclusion:
The quality of treatment has improved. In surgical staging of early ovarian cancer
is still room for improvement. Survival follow up is ongoing and should show if optimization
of baseline treatment also improves prognosis.
